Imatinib
Links shared publicly online about this topic
Oncology Medical News about Imatinib
mdlinx.com — “Elevations of creatine kinase in patients treated with imatinib mesylate (GleevecTM)” View full resource at mdlinx.com
Most Recently Shared on May 10, 2010 at 11:33 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Elevations of creatine kinase in patients treated with imatinib mesylate (GleevecTM): Leukemia Research http://bit.ly/9aZQMe #oncology
Reformulated Imatinib Eliminates Morphine Tolerance In Lab Studies
medicalnewstoday.com — “By reformulating the common cancer drug imatinib (Gleevec®), researchers have eliminated morphine tolerance in rats - an important step toward improving the effectiveness of chronic pain manag” View full resource at medicalnewstoday.com
Most Recently Shared on February 22, 2012 at 8:05 am By:
Reformulated Imatinib Eliminates Morphine Tolerance In Lab Studies http://t.co/Sawwlmfy #cancer
Imatinib can lead to remission in chronic myeloid leukemia (CML).
kevinmd.com — “Imatinib is a tyrosine kinase inhibitor that can lead to a complete cytogenetic remission in 70% of patients with chronic myeloid leukemia (CML).” View full resource at kevinmd.com
Most Recently Shared on August 28, 2011 at 3:16 pm By:
MKSAP: 58-year-old man is evaluated for increasing fatigue http://t.co/Qnj8JGC via @kevinmd
Cardiology Medical News about Hypertension, Pulmonary; Imatinib
mdlinx.com — “Imatinib in Pulmonary Arterial Hypertension Patients with Inadequate Response to Established Therapy” View full resource at mdlinx.com
Most Recently Shared on June 29, 2010 at 6:54 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Imatinib in Pulmonary Arterial Hypertension Patients with Inadequate Response to Established Therap... http://bit.ly/aEcvZk #cardio #mdlinx
New lab test could identify imatinib resistance
physorg.com — “Scientists in Japan may have developed a way to accurately predict those patients who will resist treatment with imatinib, which is the standard of care for chronic myeloid leukemia (CML).” View full resource at physorg.com
Most Recently Shared on July 29, 2010 at 4:00 am By:
PhysOrg Health News Health News
New lab test could identify imatinib resistance http://tw.physorg.com/199502839
New Lab Test Could Identify Imatinib Resistance
newswise.com — “1) Imatinib is the standard of care for chronic myeloid leukemia; 2) Fluorescence resonance energy transfer (FRET) may identify resistance; 3) FRET allows for more accurate treatment management.” View full resource at newswise.com
Most Recently Shared on July 29, 2010 at 5:30 am By:
newswise Health Communicator and Health News
New Lab Test Could Identify Imatinib Resistance: 1) Imatinib is the standard of care for chronic myeloid leukemia;... http://bit.ly/bT7Syk
Ob/Gyn Medical News about Imatinib
mdlinx.com — “Imatinib decreases endometrial stromal cell transmesothial migration and proliferation in the extracellular matrix of modeled peritoneum” View full resource at mdlinx.com
Most Recently Shared on June 13, 2010 at 8:20 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Imatinib decreases endometrial stromal cell transmesothial migration and proliferation in the extracellular ma... http://bit.ly/azLw67 #OBG
Therapeutic effect of imatinib improved with addition of chloroquine
physorg.com — “The therapeutic effects of the blockbuster leukemia drug imatinib may be enhanced when given along with a drug that inhibits a cell process called autophagy, researchers from the Kimmel Cancer Center at Jefferson reported in the Journal of Clinical Investigation.” View full resource at physorg.com
Most Recently Shared on April 13, 2009 at 10:58 pm By:
Therapeutic effect of imatinib improved with addition of chloroquine http://tinyurl.com/dfox6b
Extended imatinib improves survival in GIST | Gastroenterology Update
gastroenterologyupdate.com.au — “Extended adjuvant therapy with imatinib dramatically increases survival in patients with operable gastrointestinal stromal tumour, research presented at the American Society of Clinical Oncology annual congress shows.” View full resource at gastroenterologyupdate.com.au
Most Recently Shared on June 8, 2011 at 4:00 am By:
Gastroenterology Upd Gastroenterology and Medical Publisher
Extended imatinib improves survival in GIST http://bit.ly/iBz2L0 #gastroenterology
New lab test could identify imatinib resistance
eurekalert.org — “Scientists in Japan may have developed a way to accurately predict those patients who will resist treatment with imatinib, which is the standard of care for chronic myeloid leukemia.” View full resource at eurekalert.org
Most Recently Shared on July 30, 2010 at 2:00 pm By:
New lab test could identify imatinib resistance : http://eurekalert.org/e/3jkg @AACR #leukemia #CML
Dr. Kris Discusses the Imatinib GIST Clinical Trial
onclive.com — “Dr. Kris From Memorial Sloan-Kettering Cancer Center Discusses the Imatinib GIST Clinical Trial” View full resource at onclive.com
Most Recently Shared on June 20, 2011 at 7:15 pm By:
OncLive TV: Dr. Mark G. Kris form @sloan_kettering Discusses the Imatinib GIST Clinical Trial http://t.co/YCS1370
Insufficient New Evidence On Increased Doses Of Imatinib For Treating GISTs
medicalnewstoday.com — “NICE has been unable to recommend imatinib (Glivec) at increased doses to treat gastrointesti” View full resource at medicalnewstoday.com
Most Recently Shared on November 25, 2010 at 4:05 pm By:
MNT Gastrointestinal Health News
Insufficient New Evidence On Increased Doses Of Imatinib For Treating GISTs http://mnt.to/3N8v #gastrointestinal
Chronic Myeloid Leukemia: New Lab Test Could Identify Imatinib Resistance
medicalnewstoday.com — “Scientists in Japan may have developed a way to accurately predict those patients who will resist treatment with imatinib, which is the standard of care for chronic myeloid leukemia (CML).” View full resource at medicalnewstoday.com
Most Recently Shared on July 29, 2010 at 3:07 pm By:
Chronic Myeloid Leukemia: New Lab Test Could Identify Imatinib Resistance http://mnt.to/3GJC #lymphoma #leukemia
Who is in charge of assessing therapeutic drug monitoring? The case of imatinib : The Lancet Oncology
thelancet.com — “Who is in charge of assessing therapeutic drug monitoring? The case of imatinib. By - Thierry Buclin, Nicolas Widmer, Jerome Biollaz, Laurent A Decosterd” View full resource at thelancet.com
Most Recently Shared on January 1, 2011 at 1:06 am By:
[Comment] Who is in charge of assessing therapeutic drug monitoring? The case of imatinib: In April, 2010, the U... http://bit.ly/enqfjo
Leukemia Patients Who Do Not Respond To Interferon Benefit From Imatinib
medicalnewstoday.com — “A new study has found that patients with chronic myeloid leukemia (CML) who have not responded to interferon treatments experience long-term benefits when they switch to the targeted drug imatinib” View full resource at medicalnewstoday.com
Most Recently Shared on February 27, 2012 at 9:05 am By:
Leukemia Patients Who Do Not Respond To Interferon Benefit From Imatinib http://t.co/xcYuWciV #lymphoma #leukemia
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
Sandeep Pulim MD
Over 2K medical journal articles & health news summarized and delivered FREE to 35 specialties daily. Oncology, Rheumatology, Cardiology, Neurology, Psychiatry
-
MNT Cancer News
The latest cancer news published daily. Articles from research centers, universities and prestigious journals.
-
Lisa Marie Blaskie
RN Home Care
Advertisement
